Advertisement
Screener

Grace Therapeutics, Inc. (GRCE) Increase Decrease In Cash And Cash Equivalents

2.8 / 5 stars · 68/120 Roast Me

Grace Therapeutics, Inc. Increase Decrease In Cash And Cash Equivalents

Grace Therapeutics, Inc. (GRCE) reported Increase Decrease In Cash And Cash Equivalents of CAD 14.30 million for the 12-month period ending 2019-03-31, per its 20-F filed 2019-06-26.

Discontinued › Cash Flow › Operating Activities

ifrs-full:IncreaseDecreaseInCashAndCashEquivalents · last filed 2019-06-26

Period endIncrease Decrease In Cash And Cash Equivalents 1 monthIncrease Decrease In Cash And Cash Equivalents 12 monthIncrease Decrease In Cash And Cash Equivalents 13 month
2019-03-3114.30M CAD
20-F · filed 2019-06-26
2018-03-31-1.55M CAD
20-F · filed 2019-06-26
2017-03-31-801.00K CAD
20-F · filed 2019-06-26
6.75M CAD
20-F · filed 2019-06-26
2017-02-287.55M CAD
20-F · filed 2019-06-26
2016-02-291.72M CAD
20-F · filed 2018-06-29

Similar stocks

Stock NameCountryMarket CapPE Ratio
PDS Biotechnology Corp (PDSB)United States$0.045B
SCYNEXIS INC (SCYX)United States$0.045B
Werewolf Therapeutics, Inc. (HOWL)United States$0.047B
VERU INC. (VERU)United States$0.043B-3.93
Dogwood Therapeutics, Inc. (DWTX)United States$0.049B
Lite Strategy, Inc. (LITS)United States$0.049B
Elicio Therapeutics, Inc. (ELTX)United States$0.049B
Kairos Pharma, LTD. (KAPA)United States$0.041B
Incannex Healthcare Inc. (IXHL)$0.040B-22.32
Karyopharm Therapeutics Inc. (KPTI)United States$0.039B-0.98